Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The encouraging progression-free survival data increase our confidence in the role elacestrant could play as an endocrine therapy backbone in the combination setting

  80% confidence

• Menarini remains deeply committed to fully exploring elacestrant's potential benefit across multiple ongoing trials in both early stage and metastatic breast cancer

  80% confidence

• ELEVATE data demonstrate that elacestrant in combination with everolimus or abemaciclib shows consistent PFS benefit irrespective of ESR1 mutation status in ER+/HER2- mBC patients who experienced disease progression on endocrine therapy

  80% confidence

• The safety profile of elacestrant in combination with everolimus or abemaciclib is consistent with the known safety profiles of each drug, with no new safety signals observed

  80% confidence

• The extensive evidence for elacestrant spans monotherapy setting in EMERALD study, backed by two recent real-world data publications, and its growing potential in combination regimens

  80% confidence

Cited in these Via News reports

• Global Precision Oncology Race Intensifies as Biotech Firms Across Three Continents Target Regulatory Milestones →